Browsing Tag
AI drug discovery
15 posts
Can Insilico Medicine’s PandaClaw agentic AI platform accelerate pharma software licensing revenue growth in 2026?
Insilico Medicine launches PandaClaw, an agentic AI tool that lets biologists run autonomous multi-omics drug discovery analysis. Read what it means for pharma.
Does BioHive-2 redefine capital efficiency for Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX)?
Can BioHive-2 accelerate Recursion Pharmaceuticals’ pipeline and justify its AI infrastructure bet? Explore the strategic stakes for NASDAQ: RXRX.
NorthStrive Biosciences enters Phase III validation stage for AI-discovered drug compounds in metabolic disease research
Find out how NorthStrive Biosciences is advancing AI-driven drug discovery into Phase III biological validation for metabolic disease research.
Can AstraZeneca’s collaboration with Turbine speed up ADC drug discovery through AI simulation?
AstraZeneca joins hands with AI biotech Turbine to revolutionize antibody-drug conjugate discovery using virtual disease models and lab-in-the-loop design.
Is cloud infrastructure becoming biotech’s new competitive edge? How Absci’s cloud leap is shifting the R&D battleground
Is cloud compute now biotech’s real battleground? See why AI-powered platforms like Absci are making cloud infrastructure their secret weapon.
Inside the $6bn bet: How XtalPi and DoveTree plan to reshape drug discovery with AI and robotics
XtalPi and DoveTree strike a US$6 billion AI drug discovery deal blending quantum simulation, robotics, and biology to target complex diseases.
Why AI–CRDMO partnerships are gaining ground in early-stage drug discovery pipelines
AI–CRDMO collaborations are changing how drugs are discovered and validated. See why they’re attracting biotech startups and pharma innovators alike.
Are trillion-compound peptide libraries the next frontier in AI-powered drug design?
Discover how AI-driven peptide libraries with over a trillion compounds are reshaping drug discovery pipelines with speed, precision, and scalability.
Chai Discovery unveils Chai-2 AI breakthrough in fully de novo antibody design for next-gen drug discovery
Chai Discovery reveals Chai-2 AI breakthrough in antibody design with near 20% hit rate, outpacing traditional drug discovery methods. Learn how it transforms biotech.
XtalPi and Pfizer deepen AI-powered drug discovery alliance with enhanced molecular modeling platform for small molecule breakthroughs
XtalPi expands collaboration with Pfizer to build high-throughput AI-driven molecular modeling platform for small molecule discovery. Read the full strategic update.